BTX:NSD-Brooklyn ImmunoTherapeutics Inc. (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.72

Change

0.00 (0.00)%

Market Cap

USD 0.04B

Volume

0.30M

Avg Analyst Target

USD 9.00 (+1,154.01%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Brooklyn ImmunoTherapeutics Inc. (BTX) Stock Analysis:
Based on the Brooklyn ImmunoTherapeutics Inc. stock forecasts from 1 analysts, the average analyst target price for Brooklyn ImmunoTherapeutics Inc. is USD 9.00 over the next 12 months. Brooklyn ImmunoTherapeutics Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Brooklyn ImmunoTherapeutics Inc. is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Brooklyn ImmunoTherapeutics Inc.’s stock price was USD 0.72. Brooklyn ImmunoTherapeutics Inc.’s stock price has changed by -10.29% over the past week, -43.93% over the past month and -94.87% over the last year.

About

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

N/A

USD72.19B 9.35 7.18
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD65.33B 26.96 18.70
MRNA Moderna Inc

N/A

USD57.03B 4.22 2.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.17B 3.01 1.65
RPRX Royalty Pharma plc

N/A

USD26.82B 29.06 15.54
SGEN Seagen Inc

N/A

USD25.70B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

N/A

USD19.45B 58.02 5.06
ARGX argenx SE

N/A

USD17.61B N/A N/A

ETFs Containing BTX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -82.79% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.79% 3% F 2% F
Trailing 12 Months  
Capital Gain -94.87% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -94.87% 2% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 300.81% 96% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 300.81% 96% A 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 663.49% 4% F 2% F
Risk Adjusted Return 45.34% 83% B 74% C
Market Capitalization 0.04B 24% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.32 64% D 90% A-
Price/Book Ratio 7.05 12% F 11% F
Price / Cash Flow Ratio -1.82 42% F 61% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -15,616.18% 0% N/A 0% N/A
Return on Invested Capital -21,318.19% 0% N/A 1% F
Return on Assets -74.21% 7% F 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 6.17 40% F 25% F
Short Percent 5.42% 44% F 31% F
Beta 3.15 3% F 2% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.